A Study to Assess the Long-Term Safety of Tacrolimus Cream in the Treatment of Psoriasis
Phase 3
Completed
- Conditions
- Psoriasis
- Registration Number
- NCT00293917
- Lead Sponsor
- Astellas Pharma Inc
- Brief Summary
A study to assess the long-term safety of tacrolimus cream in the treatment of psoriasis
- Detailed Description
A long-term, open label, non-comparative, multi-center study to evaluate the safety of tacrolimus cream-B 0.1% in treating the signs and symptoms of psoriasis.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 658
Inclusion Criteria
- Clinical diagnosis of plaque psoriasis
Exclusion Criteria
- Skin disorder other than plaque psoriasis in the areas to be treated.
- Disease on only scalp
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Safety 12 months
- Secondary Outcome Measures
Name Time Method Efficacy 12 months